In a multi-year analysis of cervical precancers, data indicate that the incidence of cancers caused by human papillomavirus (HPV) types 16 and 18, which have been targeted by vaccination, has declined.
According to a new study, only about 16% of U.S. adolescents have received the complete vaccination against human papillomavirus (HPV) by the time they turn 13 years of age, despite national recommendations for vaccination at ages 11-12.
The Food and Drug Administration has approved the use of the nine-valent human papillomavirus (HPV) vaccine in women and men ages 27-45. The Advisory Committee on Immunization Practices (ACIP) is scheduled to review further information at its February 2019 meeting, with a potential vote at that time. Insurance reimbursement often is based on ACIP guidance.
The 67 National Cancer Institute-designated cancer centers and a host of other cancer organizations now are fully endorsing the goal of eliminating cancers caused by human papillomavirus (HPV) through gender-neutral HPV vaccination and evidence-based cancer screening.
Results of a recent study indicate a training intervention to aid provider communication about HPV vaccines with teen patients and their parents increased initiation and completion of the vaccine series.
Results from a large retrospective study of women undergoing cervical cancer screening indicate that overweight and obese women had an increased risk of cervical cancer compared to normal weight women.